Bausch Health Cos., Inc. (BHC)
5.67
+0.02
(+0.35%)
USD |
NYSE |
Sep 18, 16:00
6.34
+0.67
(+11.82%)
Pre-Market: 08:57
Bausch Health Cos. Enterprise Value : 22.03B for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 22.03B |
| September 17, 2026 | 22.02B |
| September 16, 2026 | 22.04B |
| September 15, 2026 | 22.03B |
| September 14, 2026 | 22.12B |
| September 11, 2026 | 22.10B |
| September 10, 2026 | 22.18B |
| September 09, 2026 | 22.21B |
| September 08, 2026 | 22.31B |
| September 04, 2026 | 22.36B |
| September 03, 2026 | 22.44B |
| September 02, 2026 | 22.46B |
| September 01, 2026 | 22.33B |
| August 31, 2026 | 22.29B |
| August 28, 2026 | 22.27B |
| August 27, 2026 | 22.27B |
| August 26, 2026 | 22.34B |
| August 25, 2026 | 22.43B |
| August 24, 2026 | 22.41B |
| August 21, 2026 | 22.32B |
| August 20, 2026 | 22.46B |
| August 19, 2026 | 22.49B |
| August 18, 2026 | 22.50B |
| August 17, 2026 | 22.37B |
| August 14, 2026 | 22.34B |
| Date | Value |
|---|---|
| August 13, 2026 | 22.28B |
| August 12, 2026 | 22.23B |
| August 11, 2026 | 22.24B |
| August 10, 2026 | 22.28B |
| August 07, 2026 | 22.25B |
| August 06, 2026 | 22.12B |
| August 05, 2026 | 22.26B |
| August 04, 2026 | 22.32B |
| August 03, 2026 | 22.53B |
| July 31, 2026 | 22.49B |
| July 30, 2026 | 22.16B |
| July 29, 2026 | 21.66B |
| July 28, 2026 | 21.60B |
| July 27, 2026 | 21.59B |
| July 24, 2026 | 21.57B |
| July 23, 2026 | 21.57B |
| July 22, 2026 | 21.61B |
| July 21, 2026 | 21.60B |
| July 20, 2026 | 21.66B |
| July 17, 2026 | 21.72B |
| July 16, 2026 | 21.75B |
| July 15, 2026 | 21.74B |
| July 14, 2026 | 21.69B |
| July 13, 2026 | 21.72B |
| July 10, 2026 | 21.70B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| InMed Pharmaceuticals, Inc. | 5.028M |
| NervGen Pharma Corp. | 156.97M |
| Milestone Pharmaceuticals, Inc. | 85.24M |
| Clearmind Medicine, Inc. | -12.42M |
| Lexaria Bioscience Corp. | 1.430M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 260.00M |
| Revenue (Quarterly) | 2.852B |
| Total Expenses (Quarterly) | 2.594B |
| EPS Diluted (Quarterly) | 0.6824 |
| Gross Profit Margin (Quarterly) | 65.04% |
| Profit Margin (Quarterly) | 9.12% |
| Earnings Yield | -52.21% |
| Operating Earnings Yield | 128.8% |
| Normalized Earnings Yield | 9.600 |